Multimodal imaging of macular telangiectasia type 2 in a pediatric patient.

Magdy Moussa, Mahmoud Leila, Omar Moussa

Open access · goldAbstract readCase Reports

In one paragraph

Article in American journal of ophthalmology case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 54% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Baseline demographic, clinical and multimodal imaging features of young patients with type 2 macular telangiectasia.International journal of retina and vitreous · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Magdy MoussaOphthalmology Department, Faculty of Medicine, Tanta University, El Bahr Street, Tanta Qism 2, Gharbia Governorate, Postal Code 31111, Tanta, Egypt.

Mahmoud LeilaRetina Department, Research Institute of Ophthalmology, 2, Al-Ahram Street, Giza, Egypt.

Omar MoussaOphthalmology Department, Faculty of Medicine, Kafr El Sheikh University, Mubarak Road, Qism Kafr El Sheikh, Kafr El Sheikh, Kafr El Sheikh Governorate, Egypt.

Kafrelsheikh University · EGResearch Institute of Ophthalmology · EGTanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe findings of multimodal imaging in non-proliferative and proliferative stages of MacTel 2 in a pediatric patient, and results of aflibercept use for treating neovascularization secondary to MacTel 2.

methodsRetrospective case report.

resultsAn 11-year-old girl with no history of systemic disease. BCVA was 20/200 and 20/40 in the right and left eyes, respectively. FFA, SS-OCT and SS-OCTA revealed proliferative and non-proliferative stages of MacTel 2 in the right and left eyes, respectively. Intravitreal aflibercept (2mg/0.05mL) was started (PRN) in the right eye. The patient received 5 injections that led to involution of macular neovascularization and improvement of BCVA by 5 lines. BCVA in the left eye remained stable.

conclusionMacTel 2 can develop in an earlier age than previously reported. SS-OCTA is an effective alternative to conventional imaging in diagnosis and follow-up especially in pediatric patients. Intravitreal aflibercept is effective in treating proliferative MacTel 2.

Indexed as

Aflibercept in proliferative MacTel 2MacTel 2 in a childMultimodal imaging in MacTel 2OCTA in MacTel 2

Identifiers

PMID33948521

DOI10.1016/j.ajoc.2021.101082

PMCPMC8080470

OpenAlexW3147085101

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.